Chat with us, powered by LiveChat

How Many People Plan to Get the COVID-19 Vaccine

How Many People Plan to Get the COVID 19 Vaccine

Published on : Mar-2022

As vaccines for the coronavirus enter review for emergency use by the Global Food and Drug Administration, the share of people who say they plan to get vaccinated has increased as the public has grown more confident that the development process will deliver a safe and effective vaccine. Despite this, public opinion on vaccines is far from uniform. A majority say they are hesitant to be among the first to receive it, and a substantial minority say they will not get vaccinated.

Current rate at which people around the Globe are getting Vaccinated

While the best vaccinations are very efficient at reducing illness and death, stopping a pandemic requires a coordinated campaign. Vaccinating 70 percent to 85 percent of the US population, according to infectious disease experts, would enable a return to normalcy.

That is a staggering level of vaccination on a worldwide basis. The objective of high levels of global immunity remains a long way off at the present rate of 42.5 million each day. Manufacturing capacity, on the other hand, is continuously expanding, and new vaccines from new producers are being introduced in the market.

The current global vaccination rate is an average of 42,483,430 doses per day. It will take another 5 months to cover 75% of the population at the current rate.

Covid 19 Vaccination race

Israel was the first to demonstrate that vaccinations may change the course of Covid infections. By February, more than 84% of individuals aged 70 and older had got two doses, making the country the world leader in early immunizations. Cases of Covid dropped quickly, and dozens of other nations saw a similar trend of immunization and recovery.

Israel is currently setting the pace, having begun vaccines on December 19th and giving over 150,000 in the days following. Israel had a head start on other nations by negotiating for supply of the Pfizer/BioNTech vaccine early on in exchange for medical data on the campaign's impact. Because of the country's strong healthcare infrastructure and public excitement for the vaccination, the rollout has been a success.

Source: Our world in data

Covid 19 vaccination doses administered per 100 people (May 17, 2021)

However, this progress is under threat. New strains have renewed epidemics, headed by the highly transmissible delta variant. Vaccines and viruses are now in a life-or-death battle. Unvaccinated individuals are at more danger than ever before.

According to the most recent statistics, even among individuals who have been vaccinated, the delta variation can cause minor cases, and those who become ill can spread the disease to others. Hospitalization and mortality are still prevented by vaccinations.

The coronavirus is believed to be a particular health danger for elderly people, who are more likely to have complicated underlying illnesses and weakened immune systems.

Those with higher family earnings, adjusted for cost of living and household size, are more likely to indicate they would be vaccinated than those with medium or lower incomes.

Key figures for the most impacted countries worldwide

Source: Statista

Since the beginning of the epidemic, there has been a pressing need to speed up vaccine research. According to the World Health Organization, more than 100 COVID-19 vaccine candidates are in clinical trials. Some vaccinations have been licensed for use by national health agencies. One of the first to be authorized was co-developed by Pfizer and BioNTech, and rollouts have begun in nations across the world.

However, it's essential to keep an eye on genetic alterations to make sure the virus doesn't evolve to the point where it can no longer be protected by vaccines. In the United Kingdom (Alpha), South Africa (Beta), Brazil (Gamma), and India, new variations of concern have been found (Delta).

What the future of vaccines looks like?

According to Fatpos Global, COVID-19 vaccinations in the future will have additional alternatives, as well as other administration and storage methods. Currently, Pfizer and Moderna vaccines must be stored at low temperatures. Healthcare facilities may find it difficult to transfer and even keep this. However, “next-generation” vaccinations in development might eliminate such barriers entirely and be administered straight at home.

Reach Out to Our Expert

Get in touch today to find out about how Evalueserve can help you mprove your processes, making you better, faster and more efficient.